AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 696
Study 23887199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume group (1 ml·kg·h of balanced Ringer's solution until the end of cystectomy and then 3 ml·kg·h until the end of surgery combined with preemptive norepinephrine infusion at an initial rate of 2 µg·kg·h)
Number of subjects: 166
Study 23887199 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 ml·kg·h of balanced Ringer's solution throughout surgery)
Number of subjects: 166
Study 23887199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume group
Number of subjects: 166
Study 23887199 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 23327960 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide combined with transcatheter arterial chemoembolization (TACE) - 10 mg arsenic trioxide by intravenous infusion for 5 hours per day, 3 days after TACE, repeated every 2 weeks for 3-4 cycles
Number of subjects: 60
Study 23327960 — intervention group
Group type: COMPARATOR
Intervention: Control group received periodic TACE alone
Number of subjects: 60
Study 23327960 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide combined with TACE
Number of subjects: 60
Study 20735160 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 100
Study 20735160 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 100
Study 18358541 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C‐CT)
Number of subjects: 0
Study 18358541 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0
Study 18358541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase cognitive therapy (A‐CT)
Number of subjects: 0
Study 15129392 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) 10000 U
Number of subjects: 9
Study 15129392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11694172 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% body weight support (BWS)
Number of subjects: 15
Study 11694172 — intervention group
Group type: COMPARATOR
Intervention: 0% body weight support (harness in place but no use of external support)
Number of subjects: 15
Study 11694172 — intervention group
Group type: COMPARATOR
Intervention: No body weight support (standard test)
Number of subjects: 15
Study 9504514 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone-marrow transplant (BMT) after preparation with cyclophosphamide and total-body irradiation
Number of subjects: 381
Study 9504514 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 381
Study 9504514 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 381
Study 8061425 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS 180549 (superparamagnetic iron oxide contrast agent)
Number of subjects: 41
Study 2661065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclosporin A (CyA)
Number of subjects: 39
Study 2661065 — intervention group
Group type: COMPARATOR
Intervention: High dose cyclosporin A (CyA)
Number of subjects: 39
Study 2661065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclosporin A (CyA) with NSAIDs
Number of subjects: 39
Study 780406 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific injection therapy
Number of subjects: 0
Study 780406 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 0
Study 31236286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (1 week at 0.6 mg daily, 3 weeks at 0.9 mg daily)
Number of subjects: 29
Study 31236286 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (1 week at 2 mg daily, 3 weeks at 3 mg daily)
Number of subjects: 29
Study 31236286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29231337 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance acupuncture at Toutongxue point, treatment for 4 weeks, once a day, 5 times a week.
Number of subjects: 40
Study 29231337 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture at a control point (3, 4 metatarsal combination), treatment for 4 weeks, once a day, 5 times a week.
Number of subjects: 40
Study 25691764 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV‐NAVA
Number of subjects: 10
Study 25691764 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 10
Study 23322818 — intervention group
Group type: EXPERIMENTAL
Intervention: MHT (Menopausal Hormone Treatment)
Number of subjects: 76
Study 23322818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 21644837 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam
Number of subjects: 90
Study 21644837 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen
Number of subjects: 90
Study 21644837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19084935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 76
Study 19084935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16404492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise (acceleration levels exceeding 3.9 g)
Number of subjects: 120
Study 16404492 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact exercise (acceleration levels exceeding 5.4 g)
Number of subjects: 120
Study 16404492 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at levels of 1.1-2.4 g
Number of subjects: 120
Study 12622303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 464
Study 12622303 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 464
Study 12622303 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 464
Study 11244343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic artificial tears, administered up to 6 times a day
Number of subjects: 158
Study 11244343 — intervention group
Group type: COMPARATOR
Intervention: Isotonic artificial tears, administered up to 6 times a day
Number of subjects: 158
Study 9256118 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP-ABVD with low-dose total-nodal irradiation (TNI)
Number of subjects: 179
Study 9256118 — intervention group
Group type: COMPARATOR
Intervention: MOPP-ABVD only (chemotherapy-only group)
Number of subjects: 179
Study 8509099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus subcutaneously administered interferon alpha‐2a
Number of subjects: 97
Study 8509099 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy plus placebo
Number of subjects: 97
Study 3512421 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and counselling reinforced by a doctor
Number of subjects: 64
Study 3512421 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard health education and counselling)
Number of subjects: 64
Study 3512421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 29415656 — intervention group
Group type: EXPERIMENTAL
Intervention: Beach chair method (n=30)
Number of subjects: 60
Study 29415656 — intervention group
Group type: COMPARATOR
Intervention: Control method (n=30)
Number of subjects: 60
Study 26654786 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six weeks
Number of subjects: 0
Study 26654786 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise)
Number of subjects: 0
Study 24286534 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Polaprezinc (PZ) enema
Number of subjects: 28
Study 24286534 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-PZ group)
Number of subjects: 28
Study 22331335 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based, multicomponent lifestyle intervention
Number of subjects: 208
Study 22331335 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 208
Study 20730637 — intervention group
Group type: EXPERIMENTAL
Intervention: Any condom use
Number of subjects: 1204
Study 20730637 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 1204
Study 20730637 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent condom use
Number of subjects: 1204
Study 17991903 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-based counseling training program
Number of subjects: 106
Study 16026492 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 1432
Study 16026492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1432
Study 12848770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol (FP/SM) 125 microg/SM 25 microg, 1 puff twice daily for 3 weeks
Number of subjects: 14
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: p16INK4A protein immunoreactivity
Number of subjects: 44
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: pRb detection
Number of subjects: 44
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 overexpression
Number of subjects: 44
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2 positivity
Number of subjects: 44
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: EBER 1/2-transcripts detection
Number of subjects: 44
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of p16INK4A and MDM2 immunoreactivity with HRS cells
Number of subjects: 44
Study 10574604 — intervention group
Group type: EXPERIMENTAL
Intervention: pRb-positive neoplastic cells in relation to p16-positive cells
Number of subjects: 44
Study 10574604 — intervention group
Group type: COMPARATOR
Intervention: Clinicopathological parameters and clinical prognostic indicators
Number of subjects: 44
Study 8917172 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking during FDG uptake period
Number of subjects: 24
Study 8917172 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking intermittently during FDG uptake period
Number of subjects: 24
Study 8917172 — intervention group
Group type: COMPARATOR
Intervention: Remaining silent during FDG uptake period
Number of subjects: 24
Study 1801564 — intervention group
Group type: EXPERIMENTAL
Intervention: Men who quit smoking
Number of subjects: 6569
Study 1801564 — intervention group
Group type: COMPARATOR
Intervention: Men who continued smoking
Number of subjects: 6569
Study 2938688 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine aspartate 37.5 g
Number of subjects: 0
Study 2938688 — intervention group
Group type: COMPARATOR
Intervention: Amino acids without arginine or aspartate (placebo)
Number of subjects: 0
Study 29530622 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (2 mg)
Number of subjects: 40
Study 29530622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29530622 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 40
Study 27495917 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested Alternatives
Number of subjects: 6375
Study 27495917 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Comparison
Number of subjects: 6375
Study 27495917 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable Justifications
Number of subjects: 6375
Study 27495917 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6375
Study 24508364 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography optimized for strain analysis including three RV apical views
Number of subjects: 40
Study 23054576 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenterics Intragastric Balloon (BIB) - saline-filled (500 ml saline + 10 ml methylene blue)
Number of subjects: 60
Study 23054576 — intervention group
Group type: COMPARATOR
Intervention: Endobag-Heliosphere - air-filled (950 ml air)
Number of subjects: 60
Study 19855926 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate given intravenously once every 3 months
Number of subjects: 158
Study 19855926 — intervention group
Group type: COMPARATOR
Intervention: 70 mg alendronate given orally once per week
Number of subjects: 158
Study 19855926 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 158
Study 19855926 — intervention group
Group type: COMPARATOR
Intervention: 70 mg alendronate
Number of subjects: 158
Study 17984108 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) increase of 10 mmHg
Number of subjects: 8093
Study 17984108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP) increase of 10 mmHg
Number of subjects: 8093
Study 17984108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) increase of 10 mmHg
Number of subjects: 8093
Study 17984108 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) increase of 10 mmHg
Number of subjects: 8093
Study 17449933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pericostal bar fixation (Group 1)
Number of subjects: 113
Study 17449933 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pericostal bar fixation (Group 2)
Number of subjects: 113
Study 17449933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral submuscular bar fixation (Group 3)
Number of subjects: 113
Study 17449933 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Group 1 and Group 3
Number of subjects: 113
Study 15339678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) 9 mg/m2 infused intravenously on days 1 and 15 followed by conventional chemotherapy (MICE regimen: mitoxantrone, cytarabine, etoposide)
Number of subjects: 57
Study 15339678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 57
Study 15339678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) and MICE regimen
Number of subjects: 57
Study 10791297 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate (MTF) 2.9 mg/kg weekly for 6 months
Number of subjects: 6
Study 10791297 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate (MTF) daily to achieve RBC AChE inhibition levels of 85.90%
Number of subjects: 6
Study 10791297 — intervention group
Group type: COMPARATOR
Intervention: Metrifonate (MTF)
Number of subjects: 6
Study 9577683 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of ito cells with smooth muscle cell anti-actin
Number of subjects: 18
Study 9577683 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between the number of ito cells and the stage of chronic hepatitis
Number of subjects: 18
Study 8449581 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HB vaccine (Engerix‐B, 20 micrograms) given to 40 susceptible health-care workers within three days of exposure (Group B)
Number of subjects: 107
Study 8449581 — intervention group
Group type: EXPERIMENTAL
Intervention: A single dose of HBIg (0.06 mg/kg) administered intramuscularly within three days of exposure followed by the first dose of vaccine (20 micrograms) (Group A)
Number of subjects: 107
Study 8449581 — intervention group
Group type: COMPARATOR
Intervention: No specific immunoprophylaxis (Group C)
Number of subjects: 107
Study 3092933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture after premedication with 100 mg meptazinol (first study)
Number of subjects: 125
Study 3092933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with 10 mg nalbuphine (second study)
Number of subjects: 125
Study 3092933 — intervention group
Group type: COMPARATOR
Intervention: Dummy acupuncture (second study)
Number of subjects: 125
Study 3092933 — intervention group
Group type: COMPARATOR
Intervention: Premedication alone (second study)
Number of subjects: 125
Study 31003138 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise intervention (30 min of moderate-to-high intensity ergometer bicycling)
Number of subjects: 84
Study 31003138 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual exercise
Number of subjects: 84
Study 31003138 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo exercise, 30 min of light stretching)
Number of subjects: 84
Study 28448667 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial rejuvenation surgery (face-lift and upper facial rejuvenation)
Number of subjects: 504
Study 25866234 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 100 ng/ml
Number of subjects: 80
Study 25866234 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 200 ng/ml
Number of subjects: 80
Study 25866234 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 300 ng/ml
Number of subjects: 80
Study 25866234 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 400 ng/ml
Number of subjects: 80
Study 25866234 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels at 500 ng/ml
Number of subjects: 80
Study 25866234 — intervention group
Group type: EXPERIMENTAL
Intervention: EtG immunoassay cutoff levels recommended for detecting alcohol use
Number of subjects: 80
Study 22936539 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weekly multiprofessional senior group meetings including a follow-up home visit
Number of subjects: 459
Study 22936539 — intervention group
Group type: COMPARATOR
Intervention: Preventive home visit
Number of subjects: 459
Study 21705273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (titrated from 0.5 mg/24 h to a maximum of 4 mg/24 h)
Number of subjects: 295
Study 21705273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (4 mg/24 h)
Number of subjects: 295
Study 21705273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (1-3 mg/24 h)
Number of subjects: 295
Study 21705273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 295
Study 19508310 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer (urea containing), applied twice daily during a 26-week maintenance phase
Number of subjects: 44
Study 19508310 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated areas)
Number of subjects: 44
Study 17067516 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Program (SP)
Number of subjects: 26
Study 17067516 — intervention group
Group type: COMPARATOR
Intervention: Conventional Management (CM)
Number of subjects: 26
Study 12542609 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (3 standard injections at 0, 30, and 60 days)
Number of subjects: 51
Study 12542609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication or vaccination)
Number of subjects: 51
Study 11460280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-row brush head
Number of subjects: 121
Study 11460280 — intervention group
Group type: COMPARATOR
Intervention: Eight-row brush head
Number of subjects: 121
Study 9379571 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution flush (3 ml)
Number of subjects: 150
Study 9379571 — intervention group
Group type: COMPARATOR
Intervention: Heparin solution flush (3 ml of 10 units heparin/ml normal saline)
Number of subjects: 150
Study 9379571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-saving implications of normal saline solution
Number of subjects: 150
Study 8405007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 150 mg b.i.d.
Number of subjects: 12
Study 8405007 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 300 mg b.i.d.
Number of subjects: 12
Study 8405007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3485119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable aspirin (10-15 mg/kg)
Number of subjects: 59
Study 3485119 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10-15 mg/kg)
Number of subjects: 59
Study 31380003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fluid therapy with 20 mL/kg of ringer lactate infusion within 90 minutes before ERCP and 3 mL/kg/h during ERCP followed by 3 mL/kg/h up to 8 hours
Number of subjects: 240
Study 31380003 — intervention group
Group type: COMPARATOR
Intervention: Control group received 1.5 mL/kg of ringer lactate infusion during ERCP up to 8 hours later
Number of subjects: 240
Study 30424738 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Active at Home programme
Number of subjects: 10
Study 30424738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 10
Study 27430401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent, methadone-maintained (CD-MM) patients
Number of subjects: 64
Study 27430401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-dependent patients (CD)
Number of subjects: 64
Study 27430401 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison (HC) participants
Number of subjects: 64
Study 25038314 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 10mg orally once a day for 12 weeks
Number of subjects: 0
Study 25038314 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no antioxidants)
Number of subjects: 0
Study 22422386 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (patient-selected music played via headphones)
Number of subjects: 100
Study 22422386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 100
Study 22422386 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 22422386 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 100
Study 22422386 — intervention group
Group type: COMPARATOR
Intervention: Music group and Control group
Number of subjects: 100
Study 21146749 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF gene therapy
Number of subjects: 27
Study 21146749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17605023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/day
Number of subjects: 420
Study 17605023 — intervention group
Group type: COMPARATOR
Intervention: Calcium/vitamin D supplements
Number of subjects: 420